Airway immune responses to COVID-19 vaccination in COPD patients and healthy subjects

COPD patients have a higher risk of developing severe illness and mortality following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection [1]. Vaccination protects against coronavirus disease 2019 (COVID-19) through the development of systemic and airway immune responses. Patients...

Full description

Saved in:
Bibliographic Details
Published inThe European respiratory journal Vol. 60; no. 2; p. 2200497
Main Authors Southworth, Thomas, Jackson, Natalie, Singh, Dave
Format Journal Article
LanguageEnglish
Published European Respiratory Society 01.08.2022
Subjects
Agora
Online AccessGet full text

Cover

More Information
Summary:COPD patients have a higher risk of developing severe illness and mortality following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection [1]. Vaccination protects against coronavirus disease 2019 (COVID-19) through the development of systemic and airway immune responses. Patients with COPD display altered humoral immunity, with reduced antibody responses compared to healthy controls [2, 3]. We studied SARS-CoV-2 vaccine-specific immune responses in COPD patients versus healthy controls, using systemic, nasal and sputum samples. Airway and blood immune responses to COVID-19 vaccination were examined in COPD patients and healthy subjects. Anti-spike IgG, but not IgA, levels were higher in airways post-vaccination, with similar responses in COPD patients and healthy subjects. https://bit.ly/3zt6D6v
Bibliography:content type line 23
SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
ISSN:0903-1936
1399-3003
1399-3003
DOI:10.1183/13993003.00497-2022